| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | 10% Owner
2 companies
Yasunori Kaneko is Director at RCUS, with reported holdings spanning 2 companies. Yasunori Kaneko's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $492K at current prices.
Yasunori Kaneko's largest disclosed position is in RCUS as Director, worth about $486K. Net of sales, the RCUS filings show accumulation of 24,133 shares.
Yasunori Kaneko has 12 Form 4 filings on record from December 2017 to June 2026, across 2 companies: Director at Arcus Biosciences (RCUS), 2018–2026; 10% Owner at Collegium Pharmaceutical (COLL), 2017.
The 23 reported transactions were 8 option or other derivative awards, 7 stock awards, 3 conversions and 2 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $331K and no sales.
The largest open-market purchase was 20,000 shares of RCUS at an average $10.06 on February 27, 2025, about $201K. Twelve months later RCUS was up 106%.